Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive BRAchytherapy in Locally Advanced CErvical Cancer
Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive BRAchytherapy in Locally Advanced CErvical Cancer
The research group on adaptive image-guided radiotherapy for locally advanced cervical carcinoma completed the protocol for the EMBRACE II study in October 2018. This study will be carried out in the next few years at the University Clinic for Radiotherapy at the Medical University of Vienna and other international partner institutes. EMBRACE II builds on the findings of the current EMBRACE study. These are already implemented in everyday clinical practice in order to further improve the accuracy of the entire therapy of cervical carcinomas, using state-of-the-art techniques of tele- and brachytherapy. The aim of the EMBRACE II study is to maintain and enhance the excellent local tumor control as well as the nodal and systemic control for all tumor stages while minimizing the adverse reaction rates for all affected organs (rectum, sigmoid, urinary bladder, and vagina) to increase the quality of life of patients with cervical carcinomas.
The standard treatment of locally advanced cervical cancer is radio-chemotherapy including external beam radiotherapy (EBRT), brachytherapy (BT) and concomitant chemotherapy with weekly Cisplatin. Image Guided Adaptive Brachytherapy (IGABT), with repetitive MRI regarded as gold standard, is increasingly recognized as the new paradigm replacing 2D BT and spreading throughout the world. This spread is at present predominantly in Europe, North America and in many places in Asia. The Gyn GEC ESTRO Recommendations I-IV have been used as the conceptual frame for these developments during the last decade and are now embedded into the new ICRU/GEC ESTRO report 88 (International Commission on Radiation and Units) which is being published in 2015.
Beside increasing mono-institutional clinical experience - also reported in literature - there is increasing clinical evidence and analyses from multi-institutional studies, in particular RetroEMBRACE (n=731) and EMBRACE (n>1350) about dose volume effects and outcome. The mature RetroEMBRACE clinical outcome data and dose volume effect analysis for disease outcome show an improved excellent local and pelvic control and survival and significant dose volume effects for IGABT. Overall treatment time was found to have significant impact on local control, and in addition, volume effects of EBRT were found (IMRT vs. 3D CRT) with impact on morbidity and quality of life. Furthermore, dose effects of chemotherapy (≥5 cycles) were found to have impact on survival in advanced disease. Comprehensive analyses from both large patient cohorts reveal further relevant treatment parameters with major impact on disease outcome, morbidity and quality of life. In the international community the results from the EMBRACE studies are regarded as benchmark for future clinical research in this field. Based on the large success of the RetroEMBRACE and EMBRACE studies, the EMBRACE study and research group decided to continue the clinical research work and to initiate a consecutive EMBRACE II study with interventions derived from the evidence collected within the EMBRACE studies.
INTERVENTIONS, AIMS AND HYPOTHESES
The EMBRACE II interventions address local, nodal and systemic treatment as well as exposure of organs at risk:
The general aims of the EMBRACE II study are:
Beside these general aims, there is a significant number of specific aims which refer to the prospective validation of dose volume parameters from the EMBRACE analyses (e.g. dose escalation for large tumors with increased application of IC/IS techniques), to explore and evaluate dose volume parameters for EBRT and to identify prognostic parameters.
General and specific hypotheses were formulated for the various interventions (BT, EBRT, chemotherapy) and endpoints (disease, morbidity, quality of life).
TYPE OF DESIGN The study is a multicenter prospective interventional study with some areas for observational research (e.g. dose-volume histogram (DVH) for IMRT). Reporting on the key patient, tumor, treatment and outcome parameters is mandatory including disease, morbidity and quality of life. Sub-studies as on adaptive IMRT and translational research are optional for cooperation between individual departments. Patient registration and reporting will be performed by the individual investigator via the internet to a central database.
PATIENTS TO BE INCLUDED Patients with newly biopsy proven squamous carcinoma, adenocarcinoma or adeno-squamous carcinoma of the uterine cervix, International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, IIB, IIIA, IIIB and IVA (and nodal status according to TNM) in whom definitive radio-chemotherapy with curative intent is planned are qualified for the study. Treatment has to include IGABT with MRI and IMRT with IGRT and ≥5 cycles of cis-Platin. Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 are also eligible but patients with further dissemination are not (M0). Patient work up and staging includes as a minimum patient characteristics with performance status and blood tests (e.g. haemoglobin, lymphocytes), tumor status (biopsy), gynaecological examination, MRI of the pelvis, abdominal CT or MRI, whole body FDG PET-CT (preferably) or at least chest CT. Further investigations are applied if necessary (e.g. cystoscopy, rectoscopy) or done according to institutional practice (e.g. laparoscopic lymph node assessment). Baseline morbidity scoring and quality of life questionnaire are mandatory.
TREATMENT OF PATIENTS IN THE TRIAL All patients will receive both EBRT and concomitant chemotherapy and BT. Summation of EBRT and BT doses will be performed by calculation of a biologically equivalent dose in 2 Gy per fraction (EQD2) using the linear-quadratic model with alpha/beta = 10 Gy for tumour effects and alpha/beta = 3 Gy for late normal tissue damage. The repair half time is assumed to be 1.5 hrs. EBRT has to be delivered as IMRT/VMAT (Volumetric Modulated Arc Therapy) with daily cone beam CT (IGRT) in 25 fractions with 1.8 Gy to a total dose of 45 Gy given in 5 weeks. Target definition is MRI based (initial GTV) for the CTV-T with an initial HR and LR CTV-T and an ITV-T (Internal Target Volume). CT or MRI based nodal Target (CTV-E) is according to risk of nodal spread "Small Pelvis", "Large Pelvis" or "Large Pelvis + Para-aortic Region". Overall CTV/ITV to PTV margin is 5 mm. Involved nodes are boosted preferably based on Positron Emission Tomography (PET) CT with 10-15 Gy and treated as simultaneous integrated boost within 5 weeks (2.2-2.4 Gy per fraction). A range for DVH parameters for the various OARs - contoured according to specific protocols - is taken into account for treatment planning. The LR CTV-T and the CTV- E will be treated with 45 Gy by use of EBRT (PTV45). Maximal treatment time including both EBRT and BT is 50 days. Brachytherapy is prescribed with dose escalation for advanced disease with large adaptive CTV-THR including IC/IS techniques and dose de-escalation for limited size CTV-THR to spare organs at risk and in particular the upper vagina. The primary imaging method is MRI with the applicator in place which enables definition of the relevant volumes of interest directly on the images for treatment planning: GTVres, adaptive CTVHR, CTVIR and organ volumes. The applicator and the reference points are reconstructed in the same image series. All treatment plans have to be optimized to achieve defined planning aims for dose and volume parameters for tumor (D98 for GTVres) and target volumes (e.g. D90-95 Gy for adaptive CTV-THR) and for 2cm3 reference volumes for OARs (e.g. <80 Gy for bladder, <65 Gy for rectum) and for vaginal reference points (recto-vaginal point < 65 Gy, PIBS). If the planning aims cannot be achieved, limits for the finally prescribed dose levels are defined for GTVres, CTVHR, CTVIR, point A, bladder, rectum, sigmoid bowel and vagina. Planning aim doses and limits for the finally prescribed dose levels are based on the experience of the previous retroEMBRACE and EMBRACE trials. For chemotherapy weekly concomitant Cisplatin (40 mg/m2) for 5-6 courses is standard unless chemotherapy is precluded by patient age, co-morbidity and toxicity. Aim is to apply minimum 5 cycles of cis-Platin, in particular in advanced disease.
QUALITY ASSURANCE Only approved departments and investigators can enroll patients into the protocol. This approval is under the responsibility of the study coordinators. The approved departments are at present those that have contributed continuously to EMBRACE in a considerable number of patients. These departments have to go additionally through a QA procedure for IMRT/IGRT. New departments will have to go through a quality assurance (QA) procedure both for IGABT and IMRT/IGRT. Approval requires a compliance questionnaire, successful training, registration and submission of cases and positive evaluation by the study coordinators for each centre. There is no formal on site monitoring, but patient files and treatment plans must be kept at least until closure of the protocol and final analysis of the results is obtained. Continuous data monitoring is performed through the study offices in Vienna and Aarhus and through Utrecht for the centres in the Netherlands. Continuous education will be offered through ACT and annual workshops and EMBRACE meetings.
OUTCOME MEASURES Local and nodal (pelvic) control within the specific EBRT and BT targets (HR-CTV-T, IR-CTV, LR CTV-T; CTV-E, CTV-N) and morbidity related to OAR in the pelvis and the para-artic region as well as overall survival, cancer specific survival and systemic control are the primary outcome measures. All endpoints will be evaluated by actuarial statistics. Morbidity will be scored by use of the Common Terminology Criteria for Adverse Events (CTCAE v3.0/4.0). QoL will also be systematically recorded in all patients.
EVALUATION OF OUTCOME MEASURES Tumor and nodal remission status (complete, uncertain complete, partial, stable & progressive disease) will be evaluated 3 months after treatment by pelvic (para-aortic, CT) MRI and gynaecological examination. Regular follow-up including gynaecological examination will then be instituted with planned appointments 6, 9, 12, 18, 24, 30, 36, 48 and 60 months after treatment. Pelvic (para-aortic, CT) MRI will be repeated at 12 months after treatment or in case of suspected recurrence. Morbidity and quality of life will be scored systematically at base line and at each time point during follow-up.
SAMPLE SIZE AND DATA MATURITY The study aims at recruiting 1000 patients in 4 years and to follow them for at least 5 years to allow for a meaningful assessment of the endpoints by univariate and multivariate analysis.
Inclusion Criteria:
Exclusion Criteria:
richard.poetter@akhwien.at0043140400 ext. 28760
karitand@rm.dk